Abstract:
The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.
Abstract:
The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.
Abstract:
The present invention relates to bispecific anti-TNF-α/IL-17A antibodies and anti-TNF-α antibodies, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Abstract:
FN3 domains that specifically bind FcγRII, their conjugates and antibody fusions, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them.
Abstract:
The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.
Abstract:
The present invention relates to bispecific anti-TNF-α/IL-17A antibodies and anti-TNF-α antibodies, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Abstract:
The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.
Abstract:
The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.
Abstract:
The present invention relates to engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions.